Literature DB >> 27324763

Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.

Jürgen Prattes1, Wiebke Duettmann2, Martin Hoenigl3.   

Abstract

Low posaconazole plasma concentrations (PPCs) have been associated with breakthrough invasive fungal infections. We assessed the correlation between pre-steady-state PPCs (obtained between days 3 and 5) and PPCs obtained during steady state in 48 patients with underlying hematological malignancies receiving posaconazole oral-solution prophylaxis. Pre-steady-state PPCs correlated significantly with PPCs obtained at steady state (Spearman r = 0.754; P < 0.001). Receiver operating characteristic (ROC) curve analysis of pre-steady-state PPCs revealed an area under the curve (AUC) of 0.884 (95% confidence interval [CI], 0.790 to 0.977) for predicting satisfactory PPCs at steady state.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27324763      PMCID： PMC4997866          DOI： 10.1128/AAC.00389-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  34 in total

1.  Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.

Authors:  Leighanne O Parkes; Matthew P Cheng; Donald C Sheppard
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

2.  Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy.

Authors:  Ryan K Shields; Cornelius J Clancy; Aniket Vadnerkar; Eun J Kwak; Fernanda P Silveira; Rima C Abdel Massih; Joseph M Pilewski; Maria Crespo; Yoshiya Toyoda; Jay K Bhama; Christian Bermudez; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

3.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

4.  Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.

Authors:  Martin Hoenigl; Wiebke Duettmann; Reinhard B Raggam; Katharina Seeber; Katharina Troppan; Sonja Fruhwald; Florian Prueller; Jasmin Wagner; Thomas Valentin; Ines Zollner-Schwetz; Albert Wölfler; Robert Krause
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

5.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

6.  Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.

Authors:  Urshila Durani; Pritish K Tosh; Jason N Barreto; Lynn L Estes; Paul J Jannetto; Aaron J Tande
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

7.  Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.

Authors:  Aaron Cumpston; Ryan Caddell; Alexandra Shillingburg; Xiaoxiao Lu; Sijin Wen; Mehdi Hamadani; Michael Craig; Abraham S Kanate
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

8.  Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.

Authors:  J J Vehreschild; M J G T Rüping; H Wisplinghoff; F Farowski; A Steinbach; R Sims; A Stollorz; K-A Kreuzer; M Hallek; C Bangard; O A Cornely
Journal:  J Antimicrob Chemother       Date:  2010-04-21       Impact factor: 5.790

9.  Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections.

Authors:  Aaron N Pham; Joseph S Bubalo; James S Lewis
Journal:  Mycoses       Date:  2016-01-06       Impact factor: 4.377

10.  Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease.

Authors:  Kim C M van der Elst; Charlie H S Brouwers; Edwin R van den Heuvel; Marjolijn J P van Wanrooy; Donald R A Uges; Tjip S van der Werf; Jos G W Kosterink; Lambert F R Span; Jan-Willem C Alffenaar
Journal:  Ther Drug Monit       Date:  2015-12       Impact factor: 3.681
View more
  7 in total

Review 1.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

2.  The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension.

Authors:  Hyeon Jeong Suh; Seo Hyun Yoon; Kyung-Sang Yu; Joo-Youn Cho; Sang-In Park; Eunyoung Lee; Jeong-Ok Lee; Youngil Koh; Kyoung-Ho Song; Pyoeng Gyun Choe; Eu Suk Kim; Soo-Mee Bang; Hong Bin Kim; Inho Kim; Nam Joong Kim; Sang Hoon Song; Wan Beom Park; Myoung-Don Oh
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 3.  Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.

Authors:  Alice J Hsu; Pranita D Tamma; Brian T Fisher
Journal:  Antimicrob Agents Chemother       Date:  2022-06-29       Impact factor: 5.938

4.  Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability.

Authors:  Martin Hoenigl; Robert Krause; David Lenczuk; Wilma Zinke-Cerwenka; Hildegard Greinix; Albert Wölfler; Jürgen Prattes; Ines Zollner-Schwetz; Thomas Valentin; Timothy C Lin; Andreas Meinitzer
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 5.  Lateral Flow Assays for the Diagnosis of Invasive Aspergillosis: Current Status.

Authors:  Sven Heldt; Martin Hoenigl
Journal:  Curr Fungal Infect Rep       Date:  2017-04-29

Review 6.  Treatment of Aspergillosis.

Authors:  Jeffrey D Jenks; Martin Hoenigl
Journal:  J Fungi (Basel)       Date:  2018-08-19

Review 7.  Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.

Authors:  Jeffrey D Jenks; Helmut Jf Salzer; Juergen Prattes; Robert Krause; Dieter Buchheidt; Martin Hoenigl
Journal:  Drug Des Devel Ther       Date:  2018-04-30       Impact factor: 4.162
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.